Alphabet Inc. (GOOGL) was reiterated a ‘Buy’ by MKM Partners analysts on Friday. The broker also cut its price target on the stock to $930 from $950, noting ad allocation shift somewhat softer in Q1.
Alphabet Inc. Cl A recently traded at $725.38, a loss of $2.69 over Thursday’s closing price. The name has a current market capitalization of $498.02 billion.
Nvidia Corporation (NVDA) was reiterated as ‘Buy’ with a $43 from $39 price target on Friday by MKM Partners. The name was also upgraded to ‘Buy’ at Topeka Capital Markets and to ‘Buy’ at ROTH Capital following earnings last night. The computer technology firm handed in Q117 EPS of $0.46 on revenue of $1.31 billion, beating Wall Street estimates of $0.41 per share on revenue of $1.26 billion.
“We are enjoying growth in all of our platforms — gaming, professional visualization, datacenter and auto,” commented Jen-Hsun Huang, co-founder and CEO, Nvidia. “Accelerating our growth is deep learning, a new computing model that uses the GPU’s massive computing power to learn artificial intelligence algorithms. Its adoption is sweeping one industry after another, driving demand for our GPUs.
NVDA currently prints a one year return of 72.57% and a year-to-date return of 8.31%.
Facebook, Inc. (FB) rating of ‘Buy’ was reiterated today at MKM Partners with a price target increase of $150 from $135 (versus a $120.28 previous close).
FB was down $0.18 at $120.10 in midday trade, moving within a 52-week range of $72 to $121.08. The name, valued at $343.48 billion, opened at $120.38.
On valuation measures, Facebook Inc. Cl A shares are currently priced at 92.87x this year’s forecasted earnings. Ticker has a t-12 price/sales ratio of 17.40. EPS for the same period registers at $1.29.
Facebook shares have advanced 8.84% in the last 4 weeks and 18.03% in the past three months. Over the past 5 trading sessions the stock has gained 2.10 percent. The $343.64 billion market cap Menlo Park, CA-based company has a median Street price target of $145 with a high target of $170.
Facebook Inc. Cl A is up 53.34% year-over-year, compared with a 2.76% loss in the S&P 500.
Shares of Allergan plc (AGN) are up $7.57 to $223.59 in midday trading despite Mizuho reiterating its ‘Neutral’ rating and decreasing the name’s 12-month base case estimate by 18 points to $232 a share. Firm said it’s lowering their price target on valuation.
Allergan plc, currently valued at $88.30 billion, has a median analyst price target of $287 with a high target of $400. Approximately 3.3 million shares have already changed hands, compared to the stock’s average daily volume of 7.43 million.
In the past 52 weeks, shares of specialty pharmaceutical company have traded between a low of $195.50 and a high of $340.34 with the 50-day MA and 200-day MA located at $232.80 and $280.26 levels, respectively.